Other ·Insufficient evidence ·Reviewed May 2026
Cannabis (THC-dominant) is not supported by NutriStack. Safety information only.
The bottom line
Evidence rating insufficient. 15 sources indexed (2007–2025), with 17 interaction records on file.
Dosing protocol
THC affects CYP enzymes, sleep architecture, and many medications. Tolerance builds rapidly.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Not recommended / non-supplement.
No effective supplement dose exists. Cost is intentionally not modeled for this regulated recreational substance. Updated 2026-05-28.
How much you'd eat to match a supplemental dose.
THC-dominant cannabis is a psychoactive drug exposure, not a nutrient with a food-equivalent target.
What to test, the optimal window inside the conventional range, and how long a response takes.
THC use produces urinary 11-nor-9-carboxy-THC (THC-COOH); detection window is 3 to 30 days depending on use frequency and body fat.
CBD-only products with under 0.3 percent THC can occasionally trigger positive screens at higher cutoffs. Hair testing extends detection to 90 days.
THC-metabolizing enzyme genetics can alter exposure to active THC and metabolites, with CYP2C9 a key pharmacogenetic concern (PMID 32712703).
Recommendation: Start low and avoid combining THC with sedatives or impairment-risk activities, especially when CYP2C9 reduced-function status is known.
Combining THC-dominant cannabis with alcohol produces additive central nervous system depression and impairment, with greater sedation, dizziness, nausea, and markedly worse psychomotor and driving performance than either alone.
Recommendation: Do not combine. The mix sharply increases impairment and accident risk; do not drive or operate machinery, and seek medical advice if severe vomiting, confusion, or loss of consciousness occurs.
Both promote sedation, so taken together they can cause additive drowsiness, grogginess, and next-day impairment.
Recommendation: Best avoided together; if combined, expect stronger sedation than either alone. Do not drive or operate machinery, and seek medical advice before combining if you take other sedating medications.
Valerian and THC-dominant cannabis both have sedative properties, so combining them can cause additive central nervous system depression and excessive drowsiness.
Recommendation: Best avoided together; the combination can produce stronger than expected sedation. Do not drive or operate machinery, and seek medical advice if combined with other CNS depressants.
Both can have sedative and CNS-depressant effects, so concurrent use may increase drowsiness and sedation.
Recommendation: Best avoided together; if combined, monitor for excessive sedation, especially when starting. Do not drive or operate machinery until effects are known, and seek medical advice if combined with other sedatives.
THC-dominant cannabis can work against the treatment goals of aripiprazole in psychosis or bipolar disorder. Continued cannabis use after a psychotic episode is linked with higher relapse rates, poorer adherence, and more antipsychotic treatment failure. Risk is highest with daily use, high-potency THC products, prior cannabis-induced psychosis, or recent hospitalization.
Recommendation: Avoid THC-dominant cannabis while taking aripiprazole for psychosis or mood stabilization. If you are already using cannabis, tell your prescriber because relapse risk and medication adherence need closer monitoring. Separating the timing of cannabis and aripiprazole does not remove this risk.
THC-dominant cannabis can undermine olanzapine treatment by increasing relapse risk and worsening psychosis outcomes. Systematic reviews link continued cannabis use in psychosis with more relapse, poorer adherence, and antipsychotic treatment failure. The combination can also add impairment and sleepiness in people already sensitive to olanzapine sedation.
Recommendation: Avoid THC-dominant cannabis while taking olanzapine for psychosis or mood stabilization. If cannabis use continues, your prescriber should know so relapse risk, adherence, and sedation can be monitored. Dose timing separation is not a reliable safety strategy.
THC-dominant cannabis can conflict with quetiapine's use for psychosis or bipolar mood stabilization. Continued cannabis use after psychosis onset is associated with higher relapse risk and poorer antipsychotic outcomes, and quetiapine's sedating effects can compound cannabis-related impairment. This is especially concerning with high-potency THC, daily use, driving, or other sedatives.
Recommendation: Avoid THC-dominant cannabis while taking quetiapine for psychosis or bipolar disorder. Tell your prescriber if you continue cannabis so they can monitor symptoms, adherence, and oversedation. Do not rely on spacing the doses to make the combination safe.
THC-dominant cannabis can interfere with risperidone's relapse-prevention role in psychosis. Continued cannabis use in people with psychotic disorders is linked with higher relapse, nonadherence, and antipsychotic treatment failure. Risk is greatest with high-potency THC, frequent use, and a history of cannabis-related psychosis.
Recommendation: Avoid THC-dominant cannabis while taking risperidone for psychosis or mood stabilization. If you are using cannabis, tell your prescriber so they can monitor relapse risk, adherence, and side effects. Timing separation does not address the main risk.
THC-dominant cannabis can raise INR and bleeding risk in people taking warfarin. Case reports describe supratherapeutic INR after recreational or medical cannabis exposure, and THC can inhibit CYP2C9, the main pathway for the more potent S-warfarin enantiomer. The risk is highest when cannabis dose, route, or frequency changes suddenly.
Recommendation: Do not start, stop, or sharply change THC-dominant cannabis use without telling your anticoagulation clinic. Ask for an INR check within 3-7 days after any change and again after the pattern stabilizes. Seek urgent care for black stools, vomiting blood, severe headache, weakness, or bleeding that does not stop.
Controlled human studies show that THC-dominant cannabis can interact meaningfully with oxycodone. One respiratory study found oxycodone reduced ventilatory response and inhaled THC did not further worsen ventilation in healthy volunteers, but THC slightly increased sedation. Another study found smoked cannabis enhanced analgesia from low-dose oxycodone and increased some oxycodone abuse-liability ratings, which can make extra dosing and impairment more likely.
Recommendation: Avoid combining THC-dominant cannabis with oxycodone unless the prescriber managing your opioid therapy knows. Do not drive, use alcohol, or add other sedatives after using both. Seek emergency help for slow breathing, inability to stay awake, repeated vomiting, confusion, or blue lips.
Direct hydrocodone-THC clinical studies are limited, but hydrocodone shares the opioid respiratory-depression and sedation liabilities studied with oxycodone. THC-dominant cannabis can add sedation, impaired attention, and coordination problems, and cannabinoid-opioid studies show clinically meaningful analgesic and behavioral interactions with oxycodone. The combination is most concerning with higher opioid doses, frequent THC use, sleep apnea, lung disease, older age, or other sedatives.
Recommendation: Do not combine THC-dominant cannabis with hydrocodone unless your opioid prescriber knows. Avoid alcohol, benzodiazepines, sleep aids, and driving after using both. Seek emergency help for severe sleepiness, slow breathing, blue lips, confusion, or inability to wake.
Albuterol can cause tremor, palpitations, tachycardia, and ECG changes, especially with repeated rescue doses or nebulized treatment. THC-dominant cannabis can also increase heart rate, worsen anxiety or dizziness, and impair coordination; smoked cannabis may add airway irritation and cough. The combination is most concerning during an asthma or COPD flare, with high-THC products, or in people with arrhythmias, coronary disease, panic symptoms, or low potassium.
Recommendation: Avoid THC-dominant cannabis when you are needing frequent albuterol or feeling palpitations, chest tightness, severe anxiety, or dizziness. Do not smoke or vape cannabis during a breathing flare. Seek urgent care for chest pain, fainting, severe shortness of breath, or a sustained racing or irregular heartbeat.
Search all 17 interaction records for Cannabis (THC-Dominant) →
Numbered references. Citations throughout the page link here.
Meta-analysis found positive associations between cannabis use and acute coronary syndrome, stroke, and cardiovascular death in real-world observational data.
Ralston MJ, Osman A. Evaluating Delta-8-THC-Induced Psychosis: A Systematic Review. Clinical neuropharmacology. 2025
Rittiphairoj T, Leslie L, Oberste JP et al.. High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. Annals of internal medicine. 2025
Groff D, Bollampally P, Buono F et al.. Interventions Addressing Cannabis Use During Pregnancy: A Systematic Review. Journal of addiction medicine. 2023
Wennberg E, Windle SB, Filion KB et al.. Roadside screening tests for cannabis use: A systematic review. Heliyon. 2023
Strand NH, Maloney J, Kraus M et al.. Cannabis for the Treatment of Fibromyalgia: A Systematic Review. Biomedicines. 2023
Phan AN, Terry GE. Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder. Frontiers in psychiatry. 2023
Sherpa ML, Shrestha N, Ojinna BT et al.. Efficacy and Safety of Medical Marijuana in Migraine Headache: A Systematic Review. Cureus. 2022
Senderovich H, Patel P, Jimenez Lopez B et al.. A Systematic Review on Cannabis Hyperemesis Syndrome and Its Management Options. Medical principles and practice : international journal of the Kuwait University, Health Science Centre. 2022
Landrigan J, Bessenyei K, Leitner D et al.. A systematic review of the effects of cannabis on cognition in people with multiple sclerosis. Multiple sclerosis and related disorders. 2022
Carvalho C, Vieira-Coelho MA. Cannabis induced psychosis: A systematic review on the role of genetic polymorphisms. Pharmacological research. 2022
Pasha AK, Clements CY, Reynolds CA et al.. Cardiovascular Effects of Medical Marijuana: A Systematic Review. The American journal of medicine. 2021
Payne KS, Mazur DJ, Hotaling JM et al.. Cannabis and Male Fertility: A Systematic Review. The Journal of urology. 2019
Meta-analysis found a small overall association between frequent cannabis use and reduced cognitive performance, with weaker effects after more than 72 hours of abstinence.
Systematic review found cannabis use associated with increased psychotic outcomes, with stronger risk estimates in more frequent users.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack